Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control
JAMA · 28.03.2023 · 329 (12) · 1024
DOI: 10.1001/jama.2023.0492 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 28.03.2023. Verfasst von Siri Lillegraven und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Withholding Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
- Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts.
- Leiden University Medical Centre, Department of Rheumatology, Leiden, the Netherlands.
Zitieren
APA
Lillegraven, S., Paulshus Sundlisæter, N., Aga, A. B., Sexton, J., Solomon, D. H., van der Heijde, D., & Haavardsholm, E. A. (2023). Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control. JAMA, 329(12), 1024. https://doi.org/10.1001/jama.2023.0492
Vancouver
Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Solomon DH, van der Heijde D, et al. Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control. JAMA. 2023;329(12):1024. doi:10.1001/jama.2023.0492
BibTeX
@article{Lillegraven2023,
author = {Lillegraven, Siri and Paulshus Sundlisæter, Nina and Aga, Anna-Birgitte and Sexton, Joseph and Solomon, Daniel H and van der Heijde, Désirée and Haavardsholm, Espen A},
title = {Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control},
journal = {JAMA},
year = {2023},
volume = {329},
number = {12},
pages = {1024},
doi = {10.1001/jama.2023.0492}
}
EUVIMED